© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Expert oncologist Michael Birrer, MD, PhD, reviews the case of a 70-year-old woman with advanced endometrial carcinoma and considers her ideal treatment pathway.
March 1st 2022
Expert perspectives on the work-up and management of a 70-year-old woman who is diagnosed with advanced endometrial carcinoma.
Focused discussion on risk factors that may drive endometrial cancer followed by advice on optimal diagnostic work-up.
A broad look at the systemic and targeted therapies available for patients diagnosed with advanced endometrial carcinoma.
Michael Birrer, MD, PhD, considers the role of pembrolizumab in advanced endometrial cancer given results from KEYNOTE-158.
Insight on the optimal sequencing of therapy in patients with advanced endometrial cancer based on MMR and MSI status.
Expert perspectives on Study 309/KEYNOTE-775, which combined pembrolizumab with lenvatinib in patients with advanced endometrial carcinoma.
Closing out his discussion on advanced endometrial carcinoma, Michael Birrer, MD, PhD, shares his hope for future treatment advances.